Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | KLF5 | Q13887 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | ATP1A1 | P05023 | 2/20 | 1.00 |
| ▸ | ATP1B1 | P05026 | 2/20 | 1.00 |
| ▸ | ATP1A3 | P13637 | 2/20 | 1.00 |
| ▸ | ATP1B2 | P14415 | 2/20 | 1.00 |
| ▸ | ATP1A2 | P50993 | 2/20 | 1.00 |
| ▸ | ATP1B3 | P54709 | 2/20 | 1.00 |
| ▸ | FXYD2 | P54710 | 2/20 | 1.00 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ouabain SCHEMBL12841141 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL14648711 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL14648716 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL24444049 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL15433 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL24951415 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL21960066 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL21960068 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL22824877 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL18922524 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121486-A1 | COMPOSITIONS AND COMPOUNDS FOR TREATING COVID-19 | INTERNATIONAL PATENT HOLDINGS LLC (KN) | 2023-06-29 | — | — | WO | claimed |
| US-8697660-B2 | Compounds and compositions for treating infection | INTERNATIONAL PATENT HOLDINGS LLC | 2014-04-15 | — | — | US | claimed |
| US-20130023487-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION | INTERNATIONAL PATENT HOLDINGS LLC (KN) | 2013-01-24 | — | — | US | claimed |
| US-11337988-B2 | Use of ouabain antagonists to inhibit viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-05-24 | — | — | US | disclosed |
| US-10137140-B2 | Therapeutic composition | Dermarc LLC (US) | 2018-11-27 | — | — | US | disclosed |
| US-10130648-B2 | Therapeutic composition | Dermarc LLC (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180133239-A1 | THERAPEUTIC COMPOSITION | MARUHO CO., LTD. (JP) | 2018-05-17 | — | — | US | disclosed |
| US-9782426-B2 | Anti-viral therapeutic composition | CUTANEA LIFE SCIENCES, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170000813-A1 | THERAPEUTIC COMPOSITION | MARUHO CO., LTD. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170000814-A1 | THERAPEUTIC COMPOSITION | MARUHO CO., LTD. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20160354396-A1 | THERAPEUTIC COMPOSITION | MARUHO CO., LTD. (JP) | 2016-12-08 | — | — | US | disclosed |
| US-20160206641-A1 | RAPIDLY-DISSOLVING THIN FILM FORMULATION OF WATER SOLUBLE DIGITALIS GLYCOSIDE FOR THE TREATMENT OF CONGESTIVE HEART DISEASE | LUMINUS BIOSCIENCES INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-20110250297-A1 | Treatment of Hyperproliferative Disorders Using Cardiac Glycosides | EPICENTRX, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130648-B2 | Therapeutic composition | CCL11, TSLP, CCL5 | SMN1; SMN2 1719/4885TP53 893/4885LMNA 2177/4885 |
| US-20170000814-A1 | THERAPEUTIC COMPOSITION | CCL11, TSLP, CCL5 | SMN1; SMN2 1719/4885TP53 893/4885LMNA 2177/4885 |
| US-11337988-B2 | Use of ouabain antagonists to inhibit viral infection | ATP1A1, ATP1A2, ATP1B1 | SMN1; SMN2 852/4885TP53 3236/4885LMNA 2216/4885 |
| US-20130023487-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION | RPN2, LSS, CLIC4 | SMN1; SMN2 4731/4885TP53 4642/4885LMNA 4592/4885 |
| US-20170000813-A1 | THERAPEUTIC COMPOSITION | CCL11, TSLP, CCL5 | SMN1; SMN2 1719/4885TP53 893/4885LMNA 2177/4885 |
| US-10137140-B2 | Therapeutic composition | CCL11, TSLP, CCL5 | SMN1; SMN2 1719/4885TP53 893/4885LMNA 2177/4885 |
| US-20180133239-A1 | THERAPEUTIC COMPOSITION | CCL11, TSLP, CCL5 | SMN1; SMN2 1719/4885TP53 893/4885LMNA 2177/4885 |
| US-20160354396-A1 | THERAPEUTIC COMPOSITION | CCL11, TSLP, CCL5 | SMN1; SMN2 1719/4885TP53 893/4885LMNA 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.